Edoxaban.png
Edoxaban (DU-176b, trade names Savaysa, Lixiana) is an oral anticoagulant drug which acts as a direct factor Xa inhibitor. It was developed by Daiichi Sankyo and approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism.
Medical uses
US FDA-labeled indications:
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant.
To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF)
Product:
Product:Edoxaban
CAS No. 480449-70-5
Molecular Formula: C24H30ClN7O4S
Molecular Weight: 548.065
Appearance: White powder
Specification: 98%
Specifications:
 the quality of our Edoxaban base
Item
Requirements
Test Results
Appearance
white  crystalline powder
Complies
Melting point
180.0℃~188.0℃
182.5℃~184.8℃
Loss on drying
≤0.50%
0.20%
Residue on ignition
≤0.20%
0.10%
Heavy Metal
 ≤20ppm
Complies
Each  impurity
≤0.50%
0.24%
T.L.C
Only one spot
Only one spot
Assay
≥98.5%
99.0%
Conclusion
Meets the Requirements
Packaging & Shipping:
Packaging Details:
25kgs packaging Fiber drum outside and plastic bag inside 1-25kgs packaging   aluminium bag outside and double plastic bag inside
Delivery Detail: within 3 days when get the payment
Shipping :
We have  Professional  shipping agent, based on customers ‘ demand for transport
By express :FEDEX,DHL,EMS ,UPS,TNT ect.
By SEA and By AIR

my contact infomation is:
Whatsapp: 008615032102186
Email: bettyapi1989@163.com

Notice: This product is only suitable for laboratory use, or the use of animals. It can not be used directly on the human body

Advertisements